Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Vir Biotechnology, Inc. (VIR) had Normalized Income after Taxes of $-65.28M for the most recently reported fiscal quarter, ending 2024-03-31.
Income Statement Financials | |
$56.38M |
|
$-65.28M |
|
$0.06M |
|
$56.32M |
|
$136.46M |
|
$-80.08M |
|
$15.08M |
|
$-65.00M |
|
$-65.00M |
|
$-65.28M |
|
$-65.28M |
|
$-65.28M |
|
Normalized Income after Taxes |
$-65.28M |
$-80.08M |
|
-- |
|
135.28M |
|
135.28M |
|
$-0.48 |
|
$-0.48 |
|
Balance Sheet Financials | |
$1.21B |
|
$92.48M |
|
$580.87M |
|
$1.79B |
|
$94.07M |
|
-- |
|
$152.54M |
|
$246.61M |
|
$1.55B |
|
$1.51B |
|
$1.55B |
|
135.84M |
|
Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |